Yu-Ju CHEN, Distinghished Research Fellow | Cited by 8,533 | of Academia Sinica, Taipei | Read 322 publications | Contact Yu-Ju CHEN

Yu-Ju Chen (Chinese: 陳玉如; pinyin: Chén Yùrú) is a Taiwanese proteomics research scientist, who leads international projects in proteogenomics. Yu-Ju Chen received a PhD in physical chemistry at Iowa State University in 1997, under the direction of Cheuk-Yiu Ng.

‪Institute of Chemistry, Academia Sinica‬ - ‪‪Cited by 9,681‬‬ - ‪Mass spectrometry‬ - ‪Proteomics‬

With great passion to reveal disease network, Yu-Ju is one of the pioneering scientists in establishing mass spectrometry-based proteomics in Taiwan. In particular, she is interested in applying these tools for in-depth exploration of the proteome network in biology and diseases.

Unintended impacts of China's Huai river policy. The impact of media censorship: 1984 or brave new world? Circular migration, or permanent stay? Evidence from China's rural–urban migration. Gaming...

YuJu is acting as senior editor of Proteomics, editorial board member of the European Journal of Mass Spectrometry, Journal of Proteome Research and Frontiers in Analytical Chemistry.

2021年11月15日 · Advanced bioinformatics-assisted mass spectrometry methods for comprehensive signatures of membrane sub-proteome and its downstream phosphoproteome and S-nitrosoproteome associated with disease.

2017年6月30日 · Professor Chen received her B.S. degree (1992) from National Taiwan University, and Ph.D. (1997) in Iowa State University. Her research interests include: 1) Advanced bioinformatics-assisted mass spectrometry methods for comprehensive signatures of membrane sub-proteome and its downstream phosphoproteome and nitrosylproteome associated with ...

Yu-Ju Chen, HUPO President, Institute of Chemistry, Academia Sinica, Taiwan It is truly a great honor and a big responsibility to serve as the HUPO president in the coming two years.

EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer. Vinculin phosphorylation impairs vascular endothelial junctions promoting atherosclerosis.